Table 1.
Correlation of EGFR and pEGFR expression with clinicopathological parameters, ER/PR, c-erbB-2, pAkt, uPAR, MMP-14 and VEGFR-1/Flt-1
| Parameters | Total | EGFR | PEGFR | |||
| n (%) | P | n (%) | P | |||
| Menopausal status | Premenopausal | 50 | 5 (10.0) | NS | 13 (26.0) | NS |
| Postmenopausal | 104 | 13 (12.5) | 42 (40.4) | |||
| Histological type | Ductal | 121 | 15 (12.4) | NS | 41 (33.9) | NS |
| Lobular | 32 | 3 (9.4) | 13 (40.6) | |||
| Histological grade | 1 | 23 | 1 (4.3) | NS | 7 (30.4) | NS |
| 2 | 90 | 11 (12.2) | 35 (38.9) | |||
| 3 | 36 | 6 (16.7) | 11 (30.6) | |||
| Nuclear grade | 1 | 53 | 1 (1.9) | 0.001 | 18 (34.0) | NS |
| 2 | 53 | 5 (9.4) | 23 (43.4) | |||
| 3 | 47 | 12 (25.5) | 13 (27.7) | |||
| Tumour size | <2 cm | 37 | 2 (5.4) | NS | 13 (35.1) | NS |
| 2 to 5 cm | 91 | 11 (12.1) | 32 (35.2) | |||
| >5 cm | 25 | 5 (20.0) | 9 (36.0) | |||
| Lymph node status | Noninfiltrated | 61 | 6 (9.8) | NS | 19 (31.1) | NS |
| Infiltrated | 91 | 12 (13.2) | 35 (38.5) | |||
| Stage | 1 | 28 | 2 (7.1) | NS | 9 (32.1) | NS |
| 2 | 97 | 12 (12.4) | 33 (34.0) | |||
| 3 | 27 | 4 (14.8) | 12 (44.4) | |||
| ER | Negative | 70 | 14 (20.0) | 0.005 | 20 (28.6) | NS |
| Positive | 83 | 4 (4.8) | 35 (42.2) | |||
| PR | Negative | 78 | 13 (16.7) | NS | 30 (38.5) | NS |
| Positive | 75 | 5 (6.7) | 25 (33.3) | |||
| c-erbB-2 | Negative(<10) | 60 | 5 (8.3) | NS | 21 (35.0) | NS |
| Positive(≥ 10) | 93 | 13 (14.0) | 34 (36.6) | |||
| pAkt | Negative (<10) | 49 | 3 (6.1) | NS | 12 (24.5) | 0.008 |
| Positive (≥ 10) | 72 | 11 (15.3) | 35 (48.6) | |||
| uPAR | Negative (<15) | 49 | 9 (18.3) | NS | 12 (24.5) | 0.049 |
| Positive (≥ 15) | 67 | 6 (9.0) | 29 (43.3) | |||
| MMP-14 | Negative (= 0) | 93 | 13 (14.0) | NS | 28 (30.1) | 0.025 |
| Positive (>0) | 29 | 2 (6.9) | 16 (55.2) | |||
| VEFGR-1/Flt-1 | Negative (<30) | 40 | 5 (12.5) | NS | 9 (22.5) | 0.016 |
| Positive (≥ 30) | 72 | 9 (12.5) | 33 (45.8) | |||
EGFR, epidermal growth factor receptor; ER, oestrogen receptor; MMP, matrix metalloproteinase; NS, not significant; pAkt, phosphorylated Akt; pEGFR, phosphorylated epidermal growth factor receptor; PR, progesterone receptor; uPAR, urokinase plasminogen activator receptor; VEGFR, vascular endothelial growth factor receptor.